Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Radioprogestins. Their clinical use]

G Skromne Kadlubik1

  • 1Depto. de Fisiología, Fac. Medicina, UNAM, México, D.F.

Ginecologia Y Obstetricia De Mexico
|October 1, 1994
PubMed
Summary

A novel radioprogestin labeled with iodine-131 shows promise for diagnosing and treating progesterone receptor-positive meningiomas. Early results in patients indicate good tumor localization and treatment response with no observed toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diagnosis and treatment of trichinosis by means of radionuclide].

Boletin medico del Hospital Infantil de Mexico·1980
Same author

[Hypophyseal gammography in man. Preliminary report].

La Prensa medica mexicana·1975
See all related articles

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmacology

Background:

  • Meningiomas are common primary brain tumors, often hormone-dependent.
  • Effective diagnostic and therapeutic agents for meningiomas are needed.

Purpose of the Study:

  • To synthesize and evaluate a novel radioprogestin (iodine-131 labeled) for meningioma diagnosis and treatment.
  • To assess the safety and efficacy of this radioprogestin in patients with hormone-dependent meningiomas.

Main Methods:

  • Synthesis of a radioprogestin labeled with iodine-131.
  • Administration of the radioprogestin to patients with meningioma for diagnostic imaging.
  • Treatment of one patient with the radioprogestin.

Main Results:

  • Successful synthesis of the radioprogestin.
  • Very good results in the scan for cerebral tumor localization in two patients.
  • Positive treatment response in one patient.
  • No radiotoxicity or intolerance observed during six months of follow-up.

Conclusions:

  • The novel radioprogestin is a promising new radiopharmaceutical for the diagnosis and treatment of progesterone receptor-positive meningiomas.
  • Further investigation is warranted to establish its role in clinical practice.

Related Experiment Videos